Hims & Hers
Hims & Hers is a consumer telehealth platform with subscription-based treatment and fulfilment.
Analyst Perspective
Hims & Hers Health, Inc. is a publicly listed consumer health company operating a direct-to-consumer telehealth platform. It connects patients with licensed healthcare providers through a digital workflow covering intake, consultation, prescribing, fulfilment, home delivery, and ongoing follow-up. Its core offers span sexual health, mental health, dermatology, weight management, hormone therapy, diagnostics, and women’s health. The business serves consumers directly under the Hims and Hers brands and uses its proprietary MedMatch system internally to support treatment matching and care personalisation. The company generates revenue primarily from recurring subscription care plans that bundle consultations, prescriptions, medication delivery, and ongoing treatment management. Additional revenue comes from one-off purchases, diagnostics, and category expansion into higher-value treatments such as weight loss and hormone health. Its strategic model is built around vertical integration, proprietary data from platform interactions, and geographic expansion beyond the United States through acquisitions and launches in Europe and Canada, with broader international ambitions stated by management.
Analyst Signal Briefing
Updated: 6 Aug 2026Hims & Hers continues to prioritise international expansion through the Zava acquisition and corporate restructuring, although recent filings confirm these moves have shifted the company from profitability to a significant net loss. Regulatory pressure has mounted following an FTC lawsuit alleging the unauthorised sharing of sensitive customer health data with major advertising platforms. Despite these legal challenges, high adherence to new product formulations has supported a robust full-year revenue guidance of $2.8 billion to $3 billion.
Explorer Tier
Start exploring for free
Start with public company intelligence. Save companies, build your first watchlist, and unlock deeper strategic insights when you are ready.
- View public Company Profiles
- Save/watch companies
- Build your first Watchlist
- Access additional market signals
Key insights about Hims & Hers
Category Differentiation
Hims & Hers is a consumer telehealth and prescription fulfilment platform, not a pure SaaS vendor or a general hospital provider. Its AI capability supports internal clinical workflows rather than functioning as a standalone foundation model business.
Hims & Hers: About
Hims & Hers operates a vertically integrated digital healthcare marketplace and service platform for consumers. It acquires demand through branded consumer channels, routes users through digital intake and licensed-provider review, converts eligible users into prescription or treatment plans, and captures downstream value through pharmacy fulfilment, recurring medication delivery, and ongoing care management. The model creates value by reducing friction in access to routine and sensitive care categories, while increasing lifetime value through subscriptions, cross-sell into adjacent conditions, and improved treatment matching supported by proprietary clinical interaction data.
How Hims & Hers Works & Monetises
Business model analysis and core revenue streams
Hims & Hers monetises primarily through recurring consumer subscriptions tied to treatment plans, prescription medications, and ongoing access to care. It also captures revenue from consultation-related services, one-off product purchases, diagnostics, and prescription fulfilment. Commercially, the model blends subscription billing, service fees embedded in care pathways, and product margin on delivered pharmaceuticals and wellness treatments. Growth is reinforced by upsell across multiple condition categories and expansion into higher-value speciality treatments.
Revenue Channels
Products & Services in Categories
Verified structural categorizations from the graph
Recent Signals (Hims & Hers)
Hims & Hers' Prescription Gummy Drives High Adherence
Hims & Hers launched a prescription Biotin + Minoxidil gummy for hair growth in June 2025. One year after launch the company surveyed 300 customers and reported an 88% daily adherence rate; 79% cited the green apple flavor as a reason for continued use and about two-thirds said the frosted glass jar packaging improved their experience. The article describes manufacturing and formulation challenges in creating a prescription-grade gummy and notes Hims & Hers' broader strategy of using design to de-stigmatize prescription products. The company reported $608.1 million in Q1 revenue in its May earnings report and gave full-year guidance of $2.8 billion to $3 billion.
Read original sourceFTC sues Hims & Hers over sharing health data
The U.S. Federal Trade Commission has sued telehealth and consumer healthcare company Hims & Hers, alleging the company shared customers’ sensitive medical and healthcare information with advertisers and major tech firms including Meta and Snap, and misled consumers about its privacy practices. The FTC's complaint, filed in a California federal court, says Hims & Hers placed pixel-sized trackers from Meta, Snap, Microsoft, Pinterest, Reddit and X that captured and shared users’ health information. The complaint also accuses the company of deceptive billing practices and creating barriers to cancellation. Hims & Hers responded that its privacy policy enables users to choose how their data is used and said it will defend against the allegations. The action continues a pattern of FTC enforcement against healthcare-related companies over third-party web trackers.
Read original sourceGrindr’s Two New Products Boost Stock Appeal
Morgan Stanley upgraded Grindr to overweight and raised its price target to $18, citing two products the bank believes can materially improve monetization. Analyst Nathan Feather highlighted an "ultra-premium" subscription tier called Edge (being tested in select U.S. markets with pricing cited around $100–$500 per month) and a telehealth offering named Woodwork, launched last year and described as a competitor to Hims. Morgan Stanley said Grindr has strong engagement and profitability potential and now expects the company could grow revenue at an 18% CAGR from 2025–2028. The stock has been weak over the prior year but shows limited analyst coverage; LSEG data indicates four of five covering analysts rate it a buy.
Read original sourceHims & Hers: Frequently Asked Questions
What is Hims & Hers?
Hims & Hers is a public consumer telehealth platform that connects patients with licensed providers and delivers prescription treatments, diagnostics, and ongoing subscription care.
Who uses Hims & Hers?
Individual consumers use Hims & Hers for discreet, convenient access to online consultations, prescription medications, weight management, mental health, dermatology, hormone health, and related care.
How does Hims & Hers make money?
It makes money mainly from recurring subscriptions, prescription fulfilment, medication sales, consultation-related services, diagnostics, and cross-sell across treatment categories.
Company Facts
- Founded
- 2017
- Headquarters
- 2261 Market Street, Suite 483, San Francisco, CA 94114
- Core Segment
- B2C Consumer App / Platform
- Company Size
- 1,001–5,000
- Official Link
- himsandhers.com